The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

This is to inform you that Glenmark Pharmaceutical, has initiated a market withdrawal of Mupirocin Ointment USP 2% (NDC 68462-180-22). Kesin Pharmaceuticals Quality Assurance was notified of this Market Withdrawal on October 8, 2025, which affects repackaged products NDC 81033-020-50 and NDC 81033-020-99. This action is being taken in accordance with 21 CFR Part 7 and is classified as a market withdrawal due to a potential failure of a long-term stability assay at the 18-month time point in the bulk material provided by Glenmark Pharmaceuticals. This measure is out of an abundance of caution to ensure patient safety.

The specific products affected by this withdrawal are listed below:

Repackaged NDC	**Pack Size**	**GTIN**
81033-020-50	1g Tube 50/Case	00381033020501
81033-020-99	1g Tube 100/Case	00381033020990

Kesin Pharma Inc. repackaged and distributed these products to Cardinal Health Pharmaceutical Distribution in the following batches and quantities.

81033-020-50

Batch Number	**Quantity**
C2501027	39
C2502038	43
C2502038	11
C2502052	38
C2502053	38
C2502066	24
C2502075	24

C2503106	24
C2504152	18
C2504153	22
C2504163	22
C2505164	22
C2505166	30

81033-020-99

Batch Number	**Quantity**
C2501030	12
C2501030	5
C2502051	13
C2503088	8
C2503105	2
C2503105	10
C2503105	4
C2503105	1
C2504159	17
C2504162	3
C2505172	8